Herantis Pharma Phase 1b clinical trial is progressing

Translation: Original published in Finnish on 1/28/2025 at 11:12 am EET.

Herantis reported in a press release that the first patient with Parkinson's disease received a test dose of the drug in the second part of the Phase 1b clinical trial. At the same time, Herantis reported additional data from the first phase of the trial showing that the concentration of HER-096 in cerebrospinal fluid is well above the minimum concentration of 50-100 ng/ml targeted in preclinical trials. We continue to believe that the results of the first part of the Phase 1b trial are positive. We commented here a few months ago on the rapid completion of the first part of the Phase 1b trial here.

Progressing as planned

The Herantis trial appears to be progressing well and we believe it is likely to be completed within the announced timeframe of H2'25. The results so far also seem to support the continuation of the clinical program, although more detailed results will probably not be available for evaluation until the completion of Phase 1b. Funding for the current phase has already been secured and the next major threshold in the HER-096 development program will be the transition to and funding of Phase II clinical trials.